Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Exelixis reported financial and operational results for the first quarter of fiscal year 2026, reflecting continued progress in its core oncology franchises and pipeline development.</li><li>The company's revenue totaled approximately $611 million, with cabozantinib (CABOMETYX) franchise net product revenues reaching $555 million, marking an 8% year-over-year increase in the U.S. and a 12.5% rise globally in collaboration with partners.</li><li>Gross-to-net deductions rose to 30.2%, attributed to increased 340B volume, Medicare-related discounts, and co-pay assistance compared to the previous quarter.</li></ul>

Exelixis reported financial and operational results for the first quarter of fiscal year 2026, reflecting continued progress in its core oncology franchises and pipeline development.The company's revenue totaled approximately $611 million, with cabozantinib (CABOMETYX) franchise net product revenues reaching $555 million, marking an 8% year-over-year increase in the U.S. and a 12.5% rise globally in collaboration with partners.Gross-to-net deductions rose to 30.2%, attributed to increased 340B volume, Medicare-related discounts, and co-pay assistance compared to the previous quarter.

Exelixis: Can NET, Meningioma, and RCC Trials Unlock a Major Pipeline Breakout?

<ul><li>Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the stage for potential growth in 2026.</li><li>The company is focused on expanding its leadership in solid tumor oncology, leveraging its established presence in GU oncology and aiming to extend this to GI indications.</li><li>For the fiscal year 2025, Exelixis recorded U.S. net product revenues from its cabozantinib franchise at approximately $2.12 billion, a 17% increase from 2024, with fourth-quarter revenues reaching $547 million, marking a 6% year-over-year growth.</li></ul>

Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the stage for potential growth in 2026.The company is focused on expanding its leadership in solid tumor oncology, leveraging its established presence in GU oncology and aiming to extend this to GI indications.For the fiscal year 2025, Exelixis recorded U.S. net product revenues from its cabozantinib franchise at approximately $2.12 billion, a 17% increase from 2024, with fourth-quarter revenues reaching $547 million, marking a 6% year-over-year growth.

Partnership Power at Exelixis: Leveraging Collaborations to De-Risk Clinical Expansion!

<ul><li>Exelixis, Inc. reported mixed results for the third quarter of 2025, reflecting both achievement and challenges in its ongoing operations.</li><li>For the period ending October 3, 2025, Exelixis demonstrated a continued strong financial performance, driven primarily by its cabozantinib franchise.</li><li>Cabozantinib experienced robust growth in both U.S. and global markets, with U.S. net product revenues growing 14% year-over-year to $543 million.</li></ul>

Exelixis, Inc. reported mixed results for the third quarter of 2025, reflecting both achievement and challenges in its ongoing operations.For the period ending October 3, 2025, Exelixis demonstrated a continued strong financial performance, driven primarily by its cabozantinib franchise.Cabozantinib experienced robust growth in both U.S. and global markets, with U.S. net product revenues growing 14% year-over-year to $543 million.

Exelixis Is Focusing On Neuroendocrine Tumors — But Is a $100 Million Windfall Next?

<ul><li>Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology company.</li><li>Revenue growth and product development are key aspects to consider when forming an investment thesis.</li><li>In terms of financial performance, Exelixis reported total revenue of $568 million, with the cabozantinib franchise contributing $520 million.</li></ul>

Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology company.Revenue growth and product development are key aspects to consider when forming an investment thesis.In terms of financial performance, Exelixis reported total revenue of $568 million, with the cabozantinib franchise contributing $520 million.

Exelixis Inc.: The Advancement in Early Clinical Pipeline & Other Major Drivers!

<ul><li>Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that warrant caution.</li><li>The company demonstrated strong financial performance, reporting significant growth in its key product, cabozantinib, which generated $513 million in net product revenue in the U.S., marking a 36% increase year-over-year.</li><li>The global net product revenue for the cabozantinib franchise was approximately $680 million.</li></ul>

Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that warrant caution.The company demonstrated strong financial performance, reporting significant growth in its key product, cabozantinib, which generated $513 million in net product revenue in the U.S., marking a 36% increase year-over-year.The global net product revenue for the cabozantinib franchise was approximately $680 million.

Exelixis Inc.: Will It Be Able To Build On The XB628 & Other Pipeline Expansion Opportunities?

United States

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases.  The Company is building a portfolio of compounds it believes could become pharmaceutical products.  Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Exelixis Inc (EXEL US)

Exelixis: Can NET, Meningioma, and RCC Trials Unlock a Major Pipeline Breakout?

Exelixis reported financial and operational results for the first quarter of fiscal year 2026, reflecting continued progress in its core oncology...

Baptista Research

Partnership Power at Exelixis: Leveraging Collaborations to De-Risk Clinical Expansion!

Exelixis, Inc. reported its financial results for the fourth quarter and full year 2025, illustrating significant developments and setting the...

Baptista Research

Exelixis Is Focusing On Neuroendocrine Tumors — But Is a $100 Million Windfall Next?

Exelixis, Inc. reported mixed results for the third quarter of 2025, reflecting both achievement and challenges in its ongoing operations. For the...

Baptista Research

Exelixis Inc.: The Advancement in Early Clinical Pipeline & Other Major Drivers!

Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology...

Baptista Research

Exelixis Inc.: Will It Be Able To Build On The XB628 & Other Pipeline Expansion Opportunities?

Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)